This study reviews our experience with 7 patients with primary Bartholin gl
and cancer (BGC) treated at the Queensland Gynaecological Cancer Centre (QC
GC) and compares this with previously published data.
A retrospective clinicopathologic review of all patients with primary BGC t
reated at QCGC from 1988 to 2000 was performed. Of the 7 patients treated,
all underwent primary surgery and 5 of the 7 patients received radiotherapy
postoperatively.
All patients presented with a local swelling or a lump. Two had associated
discharge and 2 had associated pain. Of the 7 patients, 2, 3 and 2 respecti
vely were classified as having Stage IB, II or III disease. Five of the 7 p
atients had squamous cell carcinoma (SCC), one had adenoid-cystic carcinoma
and 1 had a small-cell neuroendocrine cancer of the Bartholin gland. None
of the patients with SCC developed recurrent disease. The patient with aden
oid-cystic carcinoma experienced local recurrences at 4 years and again at
5 years and 3 months. Nine years after primary treatment she was diagnosed
with pulmonary metastases. The patient with small-cell neuroendocrine cance
r of the Bartholin gland was considered tumour-free after operation. Thorou
gh imaging, including a CT scan of her chest, abdomen and pelvis showed no
evidence of disease. She died 1 year and three months after diagnosis from
disseminated pulmonary disease.
We present the first report, of small cell neuroendocrine cancer of the Bar
tholin gland. Therapeutic principles in the management of vulval cancer at
other sites appear to be appropriate for management of BGC.